Psychological trauma and the genetic overlap between posttraumatic stress disorder and major depressive disorder

Jessica Mundy [1,2] (orcid.org/0000-0001-5513-8902), Christopher Hübel [1,2,3] (orcid.org/0000-0002-1267-8287), Joel Gelernter [5,6,7], Daniel Levey [5,6], Robin M. Murray [2,4] (orcid.org/0000-0003-0829-0519), Megan Skelton [1,2] (orcid.org/0000-0002-7619-349X), Murray B. Stein [8,9] (orcid.org/0000-0001-9564-2871), The Million Veteran Program, Post Traumatic Stress Disorder Working Group of the Psychiatric Genomics Consortium, Evangelos Vassos [1,2] (orcid.org/0000-0001-6363-0438), Gerome Breen [1,2] (orcid.org/0000-0003-2053-1792), Jonathan R. I. Coleman [1,2,](orcid.org/0000-0002-6759-0944) *

[1]Social, Genetic and Developmental Psychiatry Centre; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom

[2]UK National Institute for Health Research (NIHR) Biomedical Research Centre, South London and Maudsley National Health Service (NHS) Trust, London, United Kingdom

[3]Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

[4]Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom

[5]Division of Human Genetics, Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, United States of America

[6]Department of Psychiatry, Veterans Affairs Connecticut Healthcare Center, West Haven, Connecticut, United States of America

[7]Departments of Genetics and Neuroscience, Yale University School of Medicine, New Haven, Connecticut, United States of America

[8]Psychiatry Service, VA San Diego Healthcare System, San Diego, California, United States of America,

[9]Departments of Psychiatry and Family Medicine & Public Health, University of California San Diego, La Jolla, California, United States of America

*Email: jonathan.coleman@kcl.ac.uk; postal address: Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, De Crespigny Park, Denmark Hill, London, United Kingdom, SE5 8AF

Funding

This study represents independent research funded partly by the National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London and partly by the Lord Leverhulme Charitable Grant (Professor Robin Murray). High performance computing facilities were funded with capital equipment grants from the GSTT Charity (TR130505) and Maudsley Charity (980).

Abstract

Background: Posttraumatic stress disorder (PTSD) and major depressive disorder

(MDD) are commonly reported co-occurring mental health consequences following

psychological trauma exposure. The disorders have high genetic overlap. We

investigated whether the genetics of PTSD were associated with reported trauma in

individuals with MDD. Since trauma is associated with recurrent MDD, we also

investigated whether the genetics of PTSD were associated with episode recurrence.

Methods: Genetic correlations were estimated between PTSD and MDD in the

presence and MDD in the absence of reported exposure to psychological trauma, and

recurrent and single-episode MDD, based on genetic data from UK Biobank Mental

Health Questionnaire respondents (N=157,358). Genetic correlations were replicated

using PTSD data from the Psychiatric Genomics Consortium and Million Veteran

Program. Polygenic risk scores were generated to investigate whether individuals with

MDD who have higher genetic risk for PTSD were more likely to report psychological

trauma than those with lower genetic risk.

Results: Individuals with MDD with a higher genetic risk for PTSD were significantly

more likely to report exposure to psychological trauma than those with lower risk

[OR=1.06 (1.03-1.09) Empricial $p<0.001$]. PTSD was significantly more genetically

correlated with recurrent MDD than with MDD in the absence of reported psychological

trauma [r_g differences = ~0.2, $p<0.008$]. Participants who had experienced recurrent

depressive episodes reported significantly higher trauma rates than participants who

had experienced a single episode [$chisquare$>167, $p<0.001$].

Conclusions: Genetic risk for PTSD in individuals with MDD may influence the way

in which traumatic life events are perceived, responded to and reported.

Introduction

Symptoms of posttraumatic stress disorder (PTSD) and major depressive disorder (MDD) are the most commonly described co-occuring problems following exposure to psychological trauma (Ben Barnes *et al.*, 2018). Across epidemiological samples, approximately 50% of individuals with PTSD have a comorbid diagnosis of MDD (Kessler *et al.*, 1995; Breslau *et al.*, 1997; Rytwinski *et al.*, 2013). Similar, or occasionally higher, estimates are observed in primary care settings (Stein *et al.*, 2000; Alim *et al.*, 2006). Previously, high comorbidity rates have been attributed to the classification of shared symptoms into the two diagnostic categories (Flory and Yehuda, 2015), such as negative mood, sleep disturbances, irritability, and concentration difficulties (American Psychiatric Association, 2013). However, several studies demonstrate that the ~50% comorbidity rate does not diminish after excluding these shared symptoms from clinical diagnoses (Grubaugh *et al.*, 2010; Elhai *et al.*, 2011) suggesting the observed symptom overlap does not provide an adequate explanation. An alternative explanation might be genetic overlap between the disorders. Twin studies have previously indicated that PTSD shares genetic influences with MDD (r=0.77) and related conditions (Koenen *et al.*, 2008; Wolf *et al.*, 2010). More recently, methods based on genome-wide association studies (GWAS) have been used to explore genetic correlations (r_g), a quantitative measure of the genetic relationship between two polygenic traits (van Rheenen *et al.*, 2019). Research from the Psychiatric Genomics Consortium (PGC) reported strong, positive genetic correlations of PTSD with depressive symptoms (r_g=0.80) and with MDD (r_g=0.62) (Nievergelt *et al.*, 2019), thus supporting results from twin studies. As well as shared genetics, another potential factor involved in PTSD-MDD comorbidity is exposure to trauma. There is a complex relationship between trauma exposure and mental health

sequelae. Exposure to trauma is common (Breslau *et al.*, 1991; Kessler *et al.*, 1995).

50-90% of people will experience a traumatic event in their lifetime but only 8-12% will

go on to develop PTSD (Shah *et al.*, 2012), suggesting that certain individuals are at

greater risk of developing PTSD than others following exposure (Auxéméry, 2012;

Duncan *et al.*, 2018b; Nievergelt *et al.*, 2019). Similarly, stressful and traumatic events

are significant risk factors for MDD (Horesh *et al.*, 2008; Shapero *et al.*, 2014; Hovens,

2015), but the majority of people who are exposed do not develop the disorder

(Kessler, 1997). Therefore, similar to PTSD risk, the effects of trauma on MDD risk are

moderated by individual liability (Colodro-Conde *et al.*, 2018). Previous research has

shown that reported traumatic events are not only heritable themselves (Jay Schulz-

Heik *et al.*, 2009; Power *et al.*, 2013; Dalvie *et al.*, 2020) but also increase the SNP-

based heritability of MDD (Coleman *et al.*, 2020), demonstrating that genetic factors

influence not only on the risk of both being exposed, but also on the risk of developing

a mental health disorder following exposure.

Aims

The ~50% PTSD-MDD comorbidity rate demonstrates that not everyone responds to

psychological trauma in the same way. This may be due to genetic liability in trauma

sensitivity. No study has investigated whether the extent to which PTSD and MDD

overlap genetically is associated with exposure to psychological trauma. We

addressed this by examining genetic correlations between PTSD and four MDD

phenotypes in the UK Biobank, with replication using the largest PTSD GWASs to data

from the PGC and the Million Veteran Program (MVP). Given evidence from clinical

studies, we hypothesized that PTSD and MDD with reported trauma would have higher

genetic overlap compared to PTSD and MDD without reported trauma, which would

add further evidence for the existence of genetic variants associated with trauma

sensitivity. We also explored the genetic overlap of PTSD with single-episode MDD

and with recurrent MDD. Research has shown that the type, frequency, and severity

of traumatic events are associated with the frequency and severity of subsequent

depressive episodes (Nanni *et al.*, 2012; Hovens *et al.*, 2015; Otte *et al.*, 2016), with

childhood maltreatment being particularly associated with MDD recurrence (Danese,

2020). Accordingly, our second hypothesis was that PTSD would have greater genetic

overlap with recurrent MDD compared to single-episode MDD, under the assumption

that rates of trauma are higher among individuals with recurrent MDD. We tested the

validity of this assumption in UK Biobank participants with MDD. To further address

our research question, we generated PTSD polygenic risk scores (PRS) in UK Biobank

participants with MDD to examine whether there is an association between genetic

risk for PTSD and the reporting of traumatic events. Following the logic of our previous

hypotheses, we expected individuals with MDD with higher genetic risk for PTSD

would be more likely to report experiencing psychological trauma and would be more

likely to have experienced recurrent depressive episodes than those with lower

genetic risk for PTSD.

Methods

This study used summary statistics from previous GWAS of 1) self-reported PTSD in

UK Biobank (Nievergelt *et al.*, 2019), 2) MDD with reported psychological trauma

exposure, 3) MDD without reported psychological trauma exposure (Coleman *et al.*,

2020), 4) recurrent MDD, and 5) single-episode MDD (Coleman *et al.*, 2019). All

phenotypes were based on UK Biobank participants who responded to the follow-up

online Mental Health Questionnaire (*N*=157,358). PTSD phenotypes can reflect the

characteristics of the sample and data collection method. To examine whether our

findings were consistent across differing PTSD phenotypes, we repeated the genetic

correlations using additional sets of summary statistics (Table1). We used results from

a GWAS of mainly clinical samples of PTSD undertaken by the PGC, known as PGC

1.5 PTSD (Nievergelt *et al.*, 2019). We also repeated our analyses using the meta-

analysis of PGC 1.5 and UK Biobank PTSD, known as PGC 2 PTSD (Nievergelt *et al.*,

2019). Finally, we used a set of summary statistics from a GWAS of United States

veterans by the MVP, based on electronic health records (Stein *et al.*, 2020).

Using the MVP PTSD summary statistics, we generated PRS for participants who met

criteria for MDD in the UK Biobank. The number of cases and controls and the SNP-

based heritability (on the liability scale) of each GWAS can be found in Table 1. All

summary statistics were produced from GWAS on individuals of European ancestries.

Details of the contributing studies and phenotype definitions can be found in the

Supplementary Methods. Brief details are presented in Table 1.

Reported trauma exposure in the individuals with MDD in the UK Biobank

We tested the assumption behind our second hypothesis, which states that the rates

of trauma exposure are higher among individuals who experience recurrent as

opposed to single-episode MDD. In the UK Biobank, participants were categorised as

having experienced either recurrent or single-episode MDD, as defined by Coleman

et al. (2019). For seven traumatic life events, which were included in the Coleman et

al. (2020) definition of "reported trauma exposure" (Table 3), we compared reporting

rates between those in who met criteria for recurrent MDD and those who met criteria

for single-episode MDD. We performed chi-square tests in R to establish whether

there were differences in trauma reporting rates. Chi-square tests were considered

statistically significant if they reached or surpassed the Bonferroni-corrected alpha

(0.05/7=0.007; i.e. to correct for the seven chi-square tests performed).

Throughout this paper, any mention of trauma exposure in participants from the UK

Biobank refers specifically to retrospective self-reported psychologically traumatic

events due to the nature of data collection via an online questionnaire. The events

being reported may have occurred before, after, or concurrently with MDD episodes

(Coleman *et al.*, 2020).

Table 1: Information about the four posttraumatic stress disorder (PTSD) and four

major depressive disorder (MDD) genome-wide association study (GWAS) summary

statistics, including the original publication, characteristics of the sample, number (*N*)

of cases and controls in original GWAS, liability scale SNP-based heritability (h^2_{SNP})

and standard error (SE) from High Definition Likelihood. Details of how observed scale

h^2_{SNP} estimates were converted to the liability scale are presented in the

Supplementary Methods.

Phenotype	Paper containing original GWAS	Sample characteristics	*N* Cases	*N* Controls	h^2_{SNP} (liability scale)	SE
UK Biobank PTSD	Nievergelt et al. (2019)	Sample comprises individuals who met criteria for probable PTSD. PTSD phenotype based on self-report answers to PTSD Checklist (PCL) 6 (Civilian version) in the UK Biobank Mental Health Questionnaire.	10,389	115,799	0.20	0.009
Psychiatric Genomics Consortium 1.5 PTSD	Nievergelt et al. (2019)	Sample comprises 59 studies of PTSD. Most cases were clinically ascertained through telephone or face-to-face interviews.	12,823	35,648	0.06	0.011
Psychiatric Genomics Consortium 2 PTSD	Nievergelt et al. (2019)	Sample comprises combined UK Biobank and Psychiatric Genomics Consortium 1.5 samples.	23,212	151,447	0.06	0.006
Million Veteran Program PTSD	Stein et al. (2020)	Sample comprises United States Veterans. PTSD was algorithmically defined based on electronic health records. Confirmed war- and combat exposure: 27.5% No exposure: 29.3% Unknown exposure: 43.1%	36,301	178,107	0.06	0.015
MDD with reported trauma	Coleman et al. (2020)	Sample comprises participants who met criteria for MDD based on answers to the Composite International Diagnostic Interview Short Form (CIDI-SF) and reported at least two traumatic life events (Table 3) in the UK Biobank Mental Health Questionnaire.	13,393	10,701	0.24	0.017
MDD without	Coleman et al. (2020)	Sample comprises participants who met	9,487	39,677	0.15	0.020

reported trauma		criteria for MDD based on answers to the Composite International Diagnostic Interview Short Form (CIDI-SF) and reported no traumatic life events (Table 3) in the UK Biobank Mental Health Questionnaire.				
Recurrent MDD	Coleman et al. (2019)	Participants met criteria for MDD based on answers to the Composite International Diagnostic Interview Short Form (CIDI-SF) and reported more than one depressive episode in the UK Biobank Mental Health Questionnaire.	17,451	63,482	0.22	0.009
Single-episode MDD	Coleman et al. (2019)	Participants met criteria for MDD based on answers to the Composite International Diagnostic Interview Short Form (CIDI-SF) and reported one depressive episode in the UK Biobank Mental Health Questionnaire.	12,024	63,482	0.10	0.008

Genetic correlations

GWAS summary statistics (Table 1) were used to calculate genetic correlations based

on single nucleotide polymorphisms (SNP-based r_g) using the High Definition

Likelihood (HDL) software and the 1,029,876 quality controlled UK Biobank imputed

HapMap3 SNPs reference panel. This reference panel is based on genotypes in UK

Biobank, which were imputed to HRC and UK10K + 1000 Genomes (Ning *et al.*, 2020).

First, we calculated genetic correlations between PTSD and (i) MDD with reported

trauma, (ii) MDD without reported trauma, (iii) recurrent MDD, and (iv) single-episode

MDD within the UK Biobank. We then replicated these genetic correlations using the

PGC 1.5 PTSD phenotype, the combined PGC 2 phenotype and the MVP phenotype.

Genetic correlations were tested for a significant difference from 0 (default in HDL)

and for a difference from 1 (in Microsoft Excel, converting r_g to a chi-square as $[(r_g -$

$1)/ se]^2$). An explanation of HDL inference of genetic correlations can be found in Ning

et al. (2020). Genetic correlations were considered significantly different to 0 or to 1 if

they surpassed the Bonferroni-corrected alpha in each analysis (0.05/4=0.0125; i.e.

to correct for the four tests in each independent set of correlations).

To test the significance of the differences between the genetic correlations we

performed a block-jackknife, which uses resampling to recalculate standard errors for

the differences between two r_g estimates. Within each of the four groups of correlations

(i.e. for the four different PTSD phenotypes) we compared r_g estimates in a pairwise

fashion (i.e. each correlation pair was compared with all other pairs within the group).

This resulted in six different block-jackknife tests per PTSD phenotype. Differences

between genetic correlations were considered statistically significant if they surpassed

the Bonferroni corrected alpha (0.05/6=0.0083; i.e. to correct for the six tests).

The Supplementary Methods contains further details of the HDL analysis, including

percentage overlap between the summary statistics and the HapMap3 reference

panel.

We also ran these analyses using Linkage Disequilibrium Score Regression (LDSC),

another command line tool for estimating heritability and genetic correlations from

GWAS summary statistics (Bulik-Sullivan *et al.*, 2015). In our study, we favoured HDL

for estimating genetic correlations. Unlike LDSC, HDL uses a full likelihood-based

method to estimate genetic correlations that fully accounts for linkage disequilibrium

(LD) across the genome. When compared to LDSC, HDL reduces the variance of the

genetic correlation by approximately 60% (Ning *et al.*, 2020). Consequently, HDL is

better powered to detect significant differences between correlations, which was a

central aim of our study. The LDSC results and an explanation of any differences from

HDL are presented in the Supplementary Results.

Polygenic risk scores

We calculated individual PRS for PTSD using the MVP summary statistics in

individuals with MDD from the UK Biobank. For this, we used PRSice v2.3.1 and

controlled for the first six principal components, genotyping batch and assessment

centre. PRS were calculated at 11 *p*-value thresholds (5×10^{-8}, 1×10^{-5}, 1×10^{-3}, 0.01,

0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 1). Phenotype permutations were used to produce an

empirical *p*-value for the association at the best-fitting PRS, which accounts for testing

at multiple thresholds (Euesden *et al.*, 2015). Once the best-fitting PRS had been

calculated, we then performed logistic regressions to examine whether genetic risk for

PTSD was more strongly associated with MDD with reported trauma compared to

MDD without reported trauma, and to examine whether genetic risk for PTSD was

more strongly associated with recurrent compared to single-episode MDD. The

standardised beta coefficients were converted to odds ratios (OR) in R and 95%

confidence intervals (CI) were calculated. The full six pairwise comparisons, as in the

block-jackknife analysis in this study, were not possible due to MDD cases in the UK

Biobank belonging to overlapping MDD subtypes. Therefore, we limit the PRS analysis

to these two comparisons.

We performed power calculations using the Additive Variance Explained and Number

of Genetic Effects Method of Estimation (AVENGEME) programme in R (Dudbridge,

2013). Details of this are presented in the Supplementary Methods. The MVP

summary statistics were chosen due to their power and there being no overlap

between the individuals in this sample and the target sample (UK Biobank). Since one

target sample was used to produce PRS for the two regressions a Bonferroni

adjustment was used correcting for 2 tests and giving a final threshold of $p<0.025$.

Results

Trauma exposure in the UK Biobank

Seven traumatic life events comprised the overall definition of "trauma exposure" in

Coleman et al. (2020) (Table 3). Individuals who reported two or more events were

considered "trauma-exposed". Each of the seven life events were significantly more

commonly reported by UK Biobank participants who reported having experienced

recurrent MDD than those who had experienced single-episode MDD. This confirms

our assumption that the group of participants in the UK Biobank with recurrent MDD

demonstrate a higher rate of psychological trauma exposure than those in the single-

episode group.

Table 2: Difference in reporting rates of traumatic life events between individuals with

recurrent and single-episode major depressive disorder (MDD) in UK Biobank Mental

<ins>Health Questionnaire Respondents (N=157,358). Differences were considered</ins>

<ins>significant if they surpassed the Bonferroni adjusted alpha (p<0.007)</ins>

Trauma category	Traumatic event	Endorsement in single-episode MDD (%)	Endorsement in recurrent MDD (%)	χ^2 statistic	P-value
Childhood emotional abuse	Felt hated by a family member as a child	2,352 (8%)	5,239 (18%)	405	**3.52×10^{-16}**
Childhood emotional neglect	Did not feel loved as a child	3,122 (11%)	6,702 (23%)	497	**3.73×10^{-110}**
Childhood sexual abuse	Was sexually molested as a child	1,217 (4%)	2,690 (9%)	175	**6.39×10^{-16}**
Adulthood emotional abuse	Was belittled by a partner or ex-partner	3,887 (13%)	7,591 (26%)	371	**1.27×10^{-82}**
Adulthood physical abuse	Was physically abused by a partner or ex-partner	2,005 (7%)	3,987 (14%)	167	**4.29×10^{-38}**
Adulthood sexual abuse	Was forced to have sex against my will by a partner or ex-partner	890 (3%)	2,283 (8%)	240	**3.26×10^{-54}**
Sexual assault	Ever been a victim of sexual assault	2,247 (8%)	4,764 (16%)	292	**1.05×10^{-65}**

Genetic correlations

227   All genetic correlations were significantly different from 0. The genetic correlations

228   between both PGC 1.5 and PGC 2 PTSD and single-episode MDD were found to not

229   differ significantly from 1, although this finding is likely due to the large standard errors

230   of the r_g estimates, reflecting low power. All other genetic correlations were

231   significantly different to one (Table 4).

238   <Figure 1>

Figure 1: High Definition Likelihood (HDL) genetic correlation (r_g) estimates of four
PTSD phenotypes 1) UK Biobank posttraumatic stress disorder (PTSD), 2) Psychiatric
Genomics Consortium (PGC) PTSD 1.5, 3) PGC PTSD 2 and 4) Million Veteran
Program (MVP) PTSD with the four major depressive disorder (MDD) phenotypes.
Standard errors are shown in the error bars surrounding the r_g estimates for each
genetic correlation.

Table 3: High Definition Likelihood genetic correlation estimates (r_g) and standard
errors (SE) of 1) UK Biobank posttraumatic stress disorder (PTSD), 2) Psychiatric
Genomics Consortium (PGC) 1.5 PTSD, (3 PGC 2 PTSD and 4) Million Veteran
Program (MVP) PTSD with the four major depressive disorder (MDD) phenotypes. *P*
(diff 0) refers to *p*-value for test of r_g different from 0. *P* (diff 1) refers to *p*-value for test
of r_g different from 1. Genetic correlations were considered significant if they
surpassed the Bonferroni adjusted threshold (*p*<0.0125).

PTSD Phenotype	MDD phenotype	r_g	SE	*P* (diff 0)	*P* (diff 1)
UK Biobank PTSD	MDD with reported trauma	0.6040	0.06	4.92×10^{-28}	6.02×10^{-13}
UK Biobank PTSD	MDD without reported trauma	0.4701	0.07	2.43×10^{-10}	9.23×10^{-13}
UK Biobank PTSD	Recurrent MDD	0.7134	0.05	1.03×10^{-49}	2.55×10^{-9}
UK Biobank PTSD	Single-episode MDD	0.6466	0.07	8.35×10^{-21}	3.15×10^{-7}
PGC 1.5 PTSD	MDD with reported trauma	0.5520	0.07	1.35×10^{-13}	1.91×10^{-9}
PGC 1.5 PTSD	MDD without reported trauma	0.4841	0.11	1.22×10^{-5}	3.16×10^{-6}
PGC 1.5 PTSD	Recurrent MDD	0.6937	0.08	2.94×10^{-17}	1.91×10^{-4}
PGC 1.5 PTSD	Single-episode MDD	0.7560	0.14	7.09×10^{-8}	0.08
PGC 2 PTSD	MDD with reported trauma	0.6497	0.08	3.39×10^{-15}	2.18×10^{-5}
PGC 2 PTSD	MDD without reported trauma	0.5509	0.11	5.12×10^{-7}	4.24×10^{-5}
PGC 2 PTSD	Recurrent MDD	0.7915	0.08	8.45×10^{-22}	0.01
PGC 2 PTSD	Single-episode MDD	0.8147	0.11	5.27×10^{-13}	0.1
MVP PTSD	MDD with reported trauma	0.5397	0.09	8.77×10^{-9}	9.24×10^{-7}
MVP PTSD	MDD without reported trauma	0.4859	0.09	2.41×10^{-8}	3.58×10^{-9}
MVP PTSD	Recurrent MDD	0.5600	0.05	6.57×10^{-26}	1.33×10^{-16}
MVP PTSD	Single-episode MDD	0.6291	0.11	1.59×10^{-8}	8.61×10^{-4}

Differences between genetic correlations of PTSD and MDD phenotypes

The genetic correlation between PTSD and recurrent MDD was significantly greater

than that between PTSD and MDD without reported trauma when using the UK

Biobank, PGC 1.5 and PGC 2 phenotypes. All other genetic correlations were not

significantly different from each other (Supplementary Table 1). Genetic correlation

estimates of PTSD with MDD with reported trauma were consistently larger than those

with MDD without reported trauma, albeit not significant (p=0.14 – 0.65) (Table 4,

Supplementary Table 1). In contrast, no consistent pattern of genetic correlation was

observed between PTSD and recurrent versus single-episode MDD (Table 3,

Supplementary Table 1).

Polygenic risk scores

In individuals with MDD in the UK Biobank, those with a higher genetic risk for PTSD

were significantly more likely to report trauma than those with a lower PTSD risk

(OR=1.06 (1.03-1.09) Empirical p<0.001; Table 5). In contrast, those with a higher

genetic risk for PTSD were more likely to have experienced recurrent episodes but

this was not significant (OR=1.02 (1.00-1.05) Empirical p=0.28; Table 5). The variance

explained by the PRS was low, ranging from 0.02% to 0.13% based on varying the

assumed population prevalence of the target phenotype. See Supplementary Results

for full details of this analysis, including the number of SNPs in each PRS and the

Nagelkerke's R^2 for a range of population prevalence (Supplementary Table 4).

Table 5: Results of posttraumatic stress disorder (PTSD) polygenic risk score (PRS) regression analysis on individuals in the UK Biobank with major depressive disorder (MDD), including the odds ratio (OR) and 95% confidence intervals (CI), *p*-value (*P*) and empirical *p*-value accounting for testing at multiple thresholds (Empirical *P*). OR were considered significant if the Empirical *P* surpassed the Bonferroni adjusted threshold (Empirical *p*-value<0.025).

Regression	OR (95% CI)	*P*	Empirical *P*
MDD with reported trauma vs. MDD without reported trauma	1.06 (1.03 - 1.09)	2.11×10^{-5}	0.001
Recurrent MDD vs. single-episode MDD	1.02 (1.00 - 1.05)	0.05	0.28

Discussion

This study investigated whether the genetics of PTSD were more strongly overlapping with the genetics of MDD with reported trauma compared to MDD without reported trauma. This was based on clinical observations of high comorbidity among individuals who had been exposed to traumatic events, and evidence from genomic studies that the disorders strongly overlap in terms of additive genetic variants. We also investigated whether genetic risk for PTSD was associated with the risk of reporting trauma exposure, a trait known to be heritable, in UK Biobank participants with MDD. Across multiple PTSD GWAS, the difference in genetic correlation between PTSD and MDD with reported trauma and MDD without reported trauma was not significant. This indicates that any true difference is not large – however, we were underpowered to detect small differences in genetic correlation which means we cannot draw strong

conclusions from this analysis alone. By contrast, the findings from the PRS analysis

demonstrated that individuals with MDD with a higher genetic risk for PTSD were

significantly more likely to report traumatic life events than those who had a lower

genetic risk for PTSD.

In addition to these findings, we note that UK Biobank participants who met criteria for

recurrent MDD reported significantly higher rates of trauma exposure in comparison

to individuals who met criteria for single-episode MDD. This corroborates previous

psychiatric research which pinpoints exposure to stressful or traumatic events as a

key risk factor for subsequent recurrent MDD (Nanni *et al.*, 2012; Hovens *et al.*, 2015;

Otte *et al.*, 2016). Based upon this, we expected PTSD to show a greater genetic

correlation with recurrent MDD phenotype compared to the single-episode MDD

phenotype. However, we found no evidence of this in the genetic correlation analysis.

Furthermore, findings from the PRS analysis show that genetic risk for PTSD was not

more strongly associated with recurrent compared to single-episode MDD.

Previous research has postulated that PTSD-MDD comorbidity represents a specific

trauma-related psychiatric trait (Flory and Yehuda, 2015), perhaps indicating a

sensitivity to traumatic or stressful events. In our study, we used UK Biobank data on

traumatic life events which participants self-reported via the online Mental Health

Questionnaire. Previous research from twin studies has shown that the reporting of

trauma has a heritable basis (Jay Schulz-Heik *et al.*, 2009). More recently, genomic

studies have suggested that at least part of this heritability can be attributed to additive

genetic variants, reporting a SNP-based heritability estimate at around 18% for lifetime

trauma (Coleman *et al.*, 2020), and around 6% specifically for childhood trauma

(Dalvie *et al.*, 2020). The findings in our study from the PRS analysis suggest that

genetic liability for PTSD is associated with the reporting of psychological trauma in

those who have MDD. Experiencing trauma is common, but only a minority of

individuals develop PTSD (Auxéméry, 2012; Duncan *et al.*, 2018a; Nievergelt *et al.*,

2019). The PTSD summary statistics used to generate PRS in this study are therefore

capturing these individual differences in genetic risk for extreme, negative responses

to traumatic events. Since it is known that genetic variants are involved in the reporting

of events as traumatic and given that trauma is prerequisite for a diagnosis of PTSD,

the PTSD risk scores are therefore, in part, representative of individual differences in

sensitivity to trauma. UK Biobank participants with higher genetic risk for PTSD may

therefore be likely to evaluate events as emotionally distressing and report them

accordingly in the Mental Health Questionnaire, compared to individuals with lower

genetic risk for PTSD.

This finding is interesting in light of our hypothesis that PTSD would show higher

genetic overlap with MDD with reported trauma compared to MDD without reported

trauma. Although the genetic correlation analysis yielded no conclusive results, the

findings from the PRS analysis provide tentative evidence for an association between

the genetics of PTSD and the experience of traumatic life events in those who have

MDD. In the genetic correlation analysis, all four PTSD phenotypes (UK Biobank, PGC

1.5 and 2, and the MVP), had greater genetic overlap with MDD with reported trauma

compared to MDD without reported trauma. However, the differences between the

correlations were not significant. This may be due to the limited power of the original

GWASs from which the summary statistics were created. Given the findings from the

PRS analysis, it is possible that the greater genetic correlation between PTSD and

MDD with reported trauma, compared to MDD without reported trauma, might have

been significant if the MDD summary statistics had been produced from larger, better

powered GWASs. Therefore, replication with larger MDD GWASs will be useful in

understanding whether the differences between the correlations are due to chance.

The Genetic Links to Anxiety and Depression (GLAD) study, which aims to recruit

40,000 participants, will provide an opportunity to achieve this with sufficient power in

the future.

A further interesting finding from this study is the significantly higher genetic correlation

between PTSD and recurrent MDD compared to PTSD and MDD without reported

trauma, a finding which was consistent across the UK Biobank and PGC PTSD

phenotypes. This finding might reflect similarities in severity between PTSD and

recurrent MDD. It is known that exposure to trauma, especially in childhood, is related

to MDD that is severe and treatment resistant, as well as recurrent, in later life (Nanni

et al., 2012; Danese, 2020). Potentially, the MDD without reported trauma phenotype

may include participants who have had milder experiences of MDD, while the recurrent

MDD phenotype may capture participants with more severe MDD. Like recurrent MDD,

PTSD is a severe and disabling psychiatric disorder, where full, clinically significant

symptoms can present for months up to years following exposure. It is known that

symptoms often persist for years after remission (Kessler *et al.*, 2017). Taking this into

consideration, PTSD and recurrent MDD might share greater genetic overlap due to

similarities in symptom severity and persistence. These similarities may be shared to

a lesser extent between PTSD and MDD without reported trauma, which could explain

the significant difference between the genetic correlations. Although these conclusions

are speculative, an interesting next step would be to calculate the genetic relationship

of PTSD with mild and severe MDD in a large cohort with detailed symptom level data

on both MDD and PTSD.

Merits and limitations

We were able to use a variety of PTSD definitions from the largest GWAS of PTSD to

date, obtained from samples which recruited participants who were exhibiting differing

levels of severity and were recruited in distinct ways. These factors may influence the

phenotype's genetic sharing with MDD. To participate in the UK Biobank, individuals

visited recruitment centres for a number of hours to undergo physical assessments,

provide data and a DNA sample (Sudlow *et al.*, 2015). This level of investment may

mean that people who were experiencing severe emotional and functional impairment

were unlikely to participate. Contrastingly, the majority of the PGC's participants were

recruited directly from clinically ascertained studies of PTSD, using telephone

diagnostic interviews and face-to-face clinical assessments (Nievergelt *et al.*, 2019).

Consequently, it is reasonable to assume that, on average, the participants comprising

the PGC's data report more severe symptoms than individuals drawn from the

population without specific ascertainment for mental ill health (as is the case with the

UK Biobank). The benefit of using PTSD phenotypes from samples ascertained using

different recruitment methods is that it allowed us to examine how the genetics of MDD

differentially relates to PTSD depending on sample-specific features. We saw that the

significant difference in genetic correlation between PTSD and recurrent MDD and

MDD without reported trauma replicated when using the PGC samples, suggesting

this result is not only applicable to UK Biobank participants with PTSD.

Nonetheless, the MDD and trauma-related phenotypes were defined in UK Biobank

participants, who show a "volunteer selection bias" (Fry *et al.*, 2017) which refers to

the tendency of research participants to be more health-conscious and have a higher

level of social capital than non-participants (Manolio *et al.*, 2012). Furthermore,

individuals who completed the follow-up Mental Health Questionnaire, compared with

UK Biobank participants overall and the general population, are more likely to have a

university degree, come from a higher socioeconomic background and report fewer

disabilities and fewer chronic health problems (Davis *et al.*, 2019). Therefore, although

the UK Biobank offers the opportunity to amalgamate genetic and phenotypic in a

large, homogenous, single-population cohort, its demographic features mean the

MDD and trauma phenotypes may not be representative of the experiences of wider

populations.

In contrast to the UK Biobank and PGC, the MVP sample was limited to United States

veterans (Stein *et al.*, 2020). Therefore, an interesting finding was that the significant

difference in the genetic correlations between PTSD with recurrent MDD and with

PTSD and MDD without reported trauma did not replicate when using the MVP PTSD

phenotype. There are a number of potential explanations for this. War and combat-

related PTSD may be genetically distinct from PTSD arising from other types of

catastrophic events. For instance, the World Mental Health Survey showed that war-

and combat-related PTSD tends to be longer-lasting than other types (Kessler *et al.*,

2017), with a mean symptom duration of 161.7 months for those with combat

experience. These factors may alter the way the disorder overlaps genetically with

MDD. As shown in Table 1, at least a quarter of the sample had been exposed to

combat (Stein *et al.*, 2020). Another factor to consider is the demographics of the

sample, which overly represents males (94.4%), unlike the UK Biobank, PGC 1.5 and

PGC 2 samples, which have an almost even sex division. Previous GWAS findings

suggest that the genetics of PTSD may differ between men and women (Nievergelt *et*

al., 2019). Therefore, the lack of replication using the PTSD data from the MVP may

be attributable to sample-specific characteristics, including sex, severity and trauma

type. Overall, using varied PTSD phenotypes in our study has been helpful in

understanding how the genetics of differentially relate to MDD.

The interpretation of the results in this study is also affected by limitations of the

measure of trauma. Trauma exposure was measured retrospectively, which can lead

to inaccurate reporting of events (Colman *et al.*, 2016). The relative age of the

participants in the UK Biobank (40-69 at baseline) may compromise the accuracy of

recall of the events, particularly those in childhood (Table 2). A second issue is the

lack of temporal information regarding the onset of MDD in relation to traumatic

experiences, which means we cannot infer causality between them. This should be

recognised when considering the significantly higher rates of trauma among UK

Biobank participants with recurrent MDD compared to single-episode MDD. We

cannot assume that this association is causal or that the traumatic events happened

before the onset of MDD. To overcome this problem we could have limited the

definition of trauma to the three childhood items (Table 2) which would allow more

robust measurement of the influence of trauma exposure on the later development of

MDD. However, Coleman et al. (2020) reported that limiting the GWAS of MDD with

reported trauma to only the events in the Childhood Trauma Screener (Table 2) did

not significantly alter the SNP-based heritability of MDD, suggesting that the inclusion

of the adulthood events is valid when investigating the relationship between reported

trauma and MDD (Coleman *et al.*, 2020). Overall, although this method of assessing

trauma exposure is not ideal, it is the only feasible method for collecting large amounts

of data required for genomic analyses such as those in this study.

Lastly, our results may not generalise to non-European populations, since the GWASs

were based on participants of European ancestries only. This limitation, which means

the experiences of non-European individuals fail to be accounted for in genetics

research, is increasingly being acknowledged. Another recent PTSD GWAS from the

MVP also included individuals of African ancestries (Stein *et al.*, 2020). Sample sizes

are small but will hopefully grow as the field responds to the need for inclusivity and

diversity in its research.

Summary

We emphasise three note-worthy findings. Firstly, individuals in the UK Biobank who

have experienced recurrent depressive episodes report significantly higher rates of

traumatic life events compared to those who have experienced a single depressive

episode. This corroborates previous research which has found that trauma is strongly

associated with the development of recurrent MDD (Otte *et al.*, 2016; Danese, 2020).

Secondly, we report medium to high genetic correlations between PTSD and the four

MDD phenotypes (r_g=0.47-0.81). This is consistent with previous genome-wide

analyses demonstrating that PTSD and MDD are strongly genetically overlapping.

Lastly, we report that higher genetic risk for PTSD is associated with reporting

exposure to trauma in individuals with MDD. This could be considered evidence for a

heritable basis for trauma sensitivity which influences the way in which a person

perceives and responds to traumatic events.

Data availability

Genome-wide association study (GWAS) summary statistics for the posttraumatic stress disorder (PTSD) phenotypes were obtained from the PTSD working group of the Psychiatric Genomics Consortium and the Million Veteran Program. GWAS summary statistics for major depressive disorder (MDD) were obtained from the corresponding author (J.C.) at King's College London. UK Biobank data is available to bona fide researchers with an approved application.

Author contributions

J.M., J.C., and G.B. were responsible for study conception and design. J.C., G.B., M.B.S., The Million Veteran Program and the PTSD working group of the PGC were responsible for acquisition of the data. J.M., and J.C. and M.S. were responsible for data analysis. All authors were involved in the interpretation of the data. J.M. was responsible for drafting of the paper, under the close supervision of J.C. and G.B. All authors read, edited and approved the final manuscript before submission. All authors agree to be accountable for all aspects of the work, and in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated.

Ethics

The UK Biobank is approved by the North West Multi-centre research Committee. All procedures performed in studies involving human participants were in accordance with the ethical standards of this committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethics standards. All participants provided written

501 informed consent to participate in the study. This study has been completed under UK

502 Biobank approved study application 16577 (Professor Gerome Breen).

503 **<u>Acknowledgements</u>**

<u>Disclosures</u>

The authors declare no conflicts of interest.

<u>References</u>

Alim TN, Graves E, Mellman TA, Aigbogun N, Gray E, Lawson W, Charney DS

(2006) Trauma exposure, posttraumatic stress disorder and depression in an

African-American primary care population. *Journal of the National Medical*

Association **98**, 1630–1636.

American Psychiatric Association (2013) *Diagnostic and Statistical Manual of*

Mental Disorders. vol 5 American Psychiatric Association.

Auxéméry Y (2012) [Posttraumatic stress disorder (PTSD) as a consequence of the

interaction between an individual genetic susceptibility, a traumatogenic event and a

social context]. *L'Encephale* **38**, 373–380.

Ben Barnes J, Hayes AM, Contractor AA, Nash WP, Litz BT (2018) The structure

of co-occurring PTSD and depression symptoms in a cohort of Marines pre- and

post-deployment. *Psychiatry research* **259**, 442–449.

Breslau N, Davis GC, Andreski P, Peterson E (1991) Traumatic events and

posttraumatic stress disorder in an urban population of young adults. *Archives of*

general psychiatry **48**, 216–222.

Breslau N, Davis GC, Peterson EL, Schultz L (1997) Psychiatric sequelae of

posttraumatic stress disorder in women. *Archives of general psychiatry* **54**, 81–87.

Bulik-Sullivan BK, Loh P-R, Finucane HK, Ripke S, Yang J, Schizophrenia

Working Group of the Psychiatric Genomics Consortium … Neale BM (2015)

LD Score regression distinguishes confounding from polygenicity in genome-wide

association studies. *Nature genetics* **47**, 291–295.

Coleman JRI, Gaspar HA, Bryois J, Bipolar Disorder Working Group of the

Psychiatric Genomics Consortium, Major Depressive Disorder Working Group

of the Psychiatric Genomics Consortium, Breen G (2019) The Genetics of the

Mood Disorder Spectrum: Genome-wide Association Analyses of More Than

185,000 Cases and 439,000 Controls. *Biological psychiatry*.

Coleman JRI, Peyrot WJ, Purves KL, Davis KAS, Rayner C, Choi SW, Hübel C

… Breen G (2020) Genome-wide gene-environment analyses of major depressive

disorder and reported lifetime traumatic experiences in UK Biobank. *Molecular*

psychiatry.

Colman I, Kingsbury M, Garad Y, Zeng Y, Naicker K, Patten S … Thompson AH

(2016) Consistency in adult reporting of adverse childhood experiences.

Psychological medicine **46**, 543–549.

Colodro-Conde L, Couvy-Duchesne B, Zhu G, Coventry WL, Byrne EM, Gordon

S … Martin NG (2018) A direct test of the diathesis-stress model for depression.

Molecular psychiatry **23**, 1590–1596.

Dalvie S, Maihofer AX, Coleman JRI, Bradley B, Breen G, Brick LA …

Nievergelt CM (2020) Genomic influences on self-reported childhood maltreatment.

Translational psychiatry **10**, 38.

Danese A (2020) Annual Research Review: Rethinking childhood trauma-new

research directions for measurement, study design and analytical strategies. *Journal*

of child psychology and psychiatry, and allied disciplines **61**, 236–250.

Davis KAS, Coleman JRI, Adams M, Allen N, Breen G, Cullen B … Hotopf M

(2019) Mental Health in UK Biobank Revised. medRxiv *Epidemiology*

medrxiv;19001214v1.

Dudbridge F (2013) Power and predictive accuracy of polygenic risk scores. *PLoS*

genetics **9**, e1003348.

Duncan LE, Cooper BN, Shen H (2018a) Robust Findings From 25 Years of PTSD

Genetics Research. *Current psychiatry reports* **20**, 115.

Duncan LE, Ratanatharathorn A, Aiello AE, Almli LM, Amstadter AB, Ashley-

Koch AE … Koenen KC (2018b) Largest GWAS of PTSD (N=20 070) yields genetic

overlap with schizophrenia and sex differences in heritability. *Molecular psychiatry*

23, 666–673.

Elhai JD, de Francisco Carvalho L, Miguel FK, Palmieri PA, Primi R,

Christopher Frueh B (2011) Testing whether posttraumatic stress disorder and

major depressive disorder are similar or unique constructs. *Journal of anxiety*

disorders **25**, 404–410.

Euesden J, Lewis CM, O'Reilly PF (2015) PRSice: Polygenic Risk Score software.

Bioinformatics **31**, 1466–1468.

Flory JD, Yehuda R (2015) Comorbidity between post-traumatic stress disorder and

major depressive disorder: alternative explanations and treatment considerations.

Dialogues in clinical neuroscience **17**, 141–150.

Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, Collins R,

Allen NE (2017) Comparison of Sociodemographic and Health-Related

Characteristics of UK Biobank Participants With Those of the General Population.

American journal of epidemiology **186**, 1026–1034.

Grubaugh AL, Long ME, Elhai JD, Frueh BC, Magruder KM (2010) An

examination of the construct validity of posttraumatic stress disorder with veterans

using a revised criterion set. *Behaviour research and therapy* **48**, 909–914.

Horesh N, Klomek AB, Apter A (2008) Stressful life events and major depressive

disorders. *Psychiatry research* **160**, 192–199.

Hovens JG (2015) Emotional Scars: Impact of Childhood Trauma on Depressive

and Anxiety Disorders. *Universiteit Leiden*.

Hovens JGFM, Giltay EJ, Spinhoven P, van Hemert AM, Penninx BWJH (2015)

Impact of childhood life events and childhood trauma on the onset and recurrence of

depressive and anxiety disorders. *The Journal of clinical psychiatry* **76**, 931–938.

Jay Schulz-Heik R, Rhee SH, Silvern L, Lessem JM, Haberstick BC, Hopfer C,

Hewitt JK (2009) Investigation of genetically mediated child effects on maltreatment.

Behavior genetics **39**, 265–276.

Kessler RC (1997) The effects of stressful life events on depression. *Annual review*

of psychology **48**, 191–214.

Kessler RC, Aguilar-Gaxiola S, Alonso J, Benjet C, Bromet EJ, Cardoso G …

Koenen KC (2017) Trauma and PTSD in the WHO World Mental Health Surveys.

European journal of psychotraumatology **8**, 1353383.

Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB (1995) Posttraumatic

stress disorder in the National Comorbidity Survey. jamanetwork.com *Archives of*

general psychiatry **52**, 1048–1060.

Koenen KC, Fu QJ, Ertel K, Lyons MJ, Eisen SA, True WR, Goldberg J, Tsuang

MT (2008) Common genetic liability to major depression and posttraumatic stress

disorder in men. *Journal of affective disorders* **105**, 109–115.

Manolio TA, Weis BK, Cowie CC, Hoover RN, Hudson K, Kramer BS … Collins

FS (2012) New models for large prospective studies: is there a better way?

American journal of epidemiology **175**, 859–866.

Nanni V, Uher R, Danese A (2012) Childhood maltreatment predicts unfavorable

course of illness and treatment outcome in depression: a meta-analysis. *The*

American journal of psychiatry **169**, 141–151.

Nievergelt CM, Maihofer AX, Klengel T, Atkinson EG, Chen C-Y, Choi KW,

Coleman JRI, Dalvie S, Duncan LE, Gelernter J, Levey DF, Logue MW,

Polimanti R, Provost AC, Ratanatharathorn A, Stein MB, Torres K, Aiello AE,

Almli LM, Amstadter AB, Andersen SB, Andreassen OA, Arbisi PA, Ashley-

Koch AE … Koenen KC (2019) International meta-analysis of PTSD genome-wide

association studies identifies sex- and ancestry-specific genetic risk loci. *Nature*

communications **10**, 4558.

Ning Z, Pawitan Y, Shen X (2020) High-definition likelihood inference of genetic

correlations across human complex traits. *Nature genetics* **52**, 859–864.

Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M … Schatzberg AF

(2016) Major depressive disorder. *Nature reviews. Disease primers* **2**, 16065.

Power RA, Wingenbach T, Cohen-Woods S, Uher R, Ng MY, Butler AW …

McGuffin P (2013) Estimating the heritability of reporting stressful life events

captured by common genetic variants. *Psychological medicine* **43**, 1965–1971.

van Rheenen W, Peyrot WJ, Schork AJ, Lee SH, Wray NR (2019) Genetic

correlations of polygenic disease traits: from theory to practice. *Nature reviews.*

Genetics.

Rytwinski NK, Scur MD, Feeny NC, Youngstrom EA (2013) The co-occurrence of

major depressive disorder among individuals with posttraumatic stress disorder: a

meta-analysis. *Journal of Traumatic Stress* **26**, 299–309.

Shah R, Shah A, Links P (2012) Post-traumatic stress disorder and depression

comorbidity: severity across different populations. *Neuropsychiatry* **2**, 521–529.

Shapero BG, Black SK, Liu RT, Klugman J, Bender RE, Abramson LY, Alloy LB

(2014) Stressful life events and depression symptoms: the effect of childhood

emotional abuse on stress reactivity. *Journal of clinical psychology* **70**, 209–223.

Stein MB, Levey DF, Cheng Z, Wendt FR, Harrington K, Cho K … Gelernter J

(2020) Genomic Characterization of Posttraumatic Stress Disorder in a Large US

Military Veteran Sample. *BioRxiv*.

Stein MB, McQuaid JR, Pedrelli P, Lenox R, McCahill ME (2000) Posttraumatic

stress disorder in the primary care medical setting. *General hospital psychiatry* **22**,

261–269.

Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J … Collins R (2015)

UK biobank: an open access resource for identifying the causes of a wide range of

complex diseases of middle and old age. *PLoS medicine* **12**, e1001779.

Wolf EJ, Miller MW, Krueger RF, Lyons MJ, Tsuang MT, Koenen KC (2010)

Posttraumatic stress disorder and the genetic structure of comorbidity. *Journal of*

abnormal psychology **119**, 320–330.

MDD with reported trauma   * MDD without reported trauma   △ Recurrent MDD   × Single-episode MDD